TrialPloS one2026

Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.

Rodrigo Martinez Alcala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.